Considerations when initiating psoriasis patients on biologic therapy

Journal of Drugs in Dermatology

Volumn 11, Issue 5, 2012, Pages

  Zeichner, Joshua A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BRIAKINUMAB; DIPHTHERIA TETANUS VACCINE; ETANERCEPT; GOLIMUMAB; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; ISONIAZID; PNEUMOCOCCUS VACCINE; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; CROHN DISEASE; DIPHTHERIA; DRUG DOSE INCREASE; HEART DEATH; HEART INFARCTION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HUMAN; INFLUENZA; JUVENILE RHEUMATOID ARTHRITIS; LATENT TUBERCULOSIS; PNEUMOCOCCAL INFECTION; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; STROKE; TETANUS; ULCERATIVE COLITIS;

BIOLOGICAL AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; PSORIASIS;

EID: 84860907909     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Stern, RS, Nijsten, T Feldman, SR, Margolis, DJ, Rolstad, T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc. 2004;9:136-139. (Pubitemid 38457271)
2. Kurd, SK and Gelfand, JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2009;60(2):218-224.
3. Neimann, AL, Porter, SB, Gelfand, JM. The epidemiology of psoriasis. Expert Rev Dermatol. 2006;1(1):63-75.
4. Gottlieb AB, Chao, C, Dann, F. Psoriasis comorbidities. J Dermatol Treat. 2008;19:5-21. (Pubitemid 351252710)
5. Menter A, Gottleib A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatology. 2008;58:826-850. (Pubitemid 351509656)
6. Van Voorhees AS and Fried R. Depression and quality of life in psoriasis. Postgrad Med. 2009;121(4):154-161.
7. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet. 2007;370:272-284. (Pubitemid 47071926)
8. Van Voorhees A, Feldman SR, Koo JYM, et al. The Psoriasis and Psoriatic Arthritis Pocket Guide. National Psoriasis Foundation. Portland, OR: 2009.
9. Humira [package insert]. North Chicago, IL: Abbott Laboratories; Nov 2009.
10. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and openlabel extension study. Am Acad Dermatol. 2006;55(4):598-606. (Pubitemid 44436647)
11. Enbrel [package insert]. Thousand Oaks, CA: Immunex Corporation; June 2010.
12. Remicade [package insert]. Jannsen Biotech, Inc. Horsham, PA. October 2011.
13. Stelara [package insert]. Horsham, PA:Centocor Ortho Biotech Inc.; Dec 2009.
14. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1681.
15. Desai SB, Furst DE. Problems encountered during anti-tumor necrosis factor therapy. Best Pract Res. 2006;20:757-790. (Pubitemid 44350122)
16. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60(7):1884-1894.
17. Lebwohl M, Bagel J, Gelfand JM, et al. From the medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58:94-105. (Pubitemid 350302037)
18. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209-217.
19. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65:191-194. (Pubitemid 43131992)
20. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272-279.
21. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31:1356-1361. (Pubitemid 38879202)
22. Duchini A, Goss JA, Karpen S, Pockros PJ. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev. 2003;16:357-364. (Pubitemid 36871311)
23. Avery RK. Immunizations in adult immunocompromised patients: which to use and which to avoid. Cleve Clin J Med. 2001;68:337-348. (Pubitemid 32303602)
24. Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci. 1997;42:2487-2494. (Pubitemid 28103785)
25. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumor necrosis factor alpha antagonists on serum transaminases and viremia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis. 2003;62:1078-1082. (Pubitemid 37323572)
26. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315-22. (Pubitemid 40254244)
27. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358:241-251.
28. Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol. 2003;139:1425-1429. (Pubitemid 37433132)
29. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol. 2006;126:2194-2201. (Pubitemid 44413165)
30. Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum. 2005;34:819-836. (Pubitemid 40740207)
31. Reich K, Papp KA, Griffiths CE, et al. An update on the longterm safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300-312.
32. Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012;132(2): 304-314.